Immutep Initiates Phase III Trial for Lung Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2024
0mins
Source: Business Insider
Immutep Ltd Update: Immutep Limited has initiated the TACTI-004 Phase III trial to evaluate its LAG-3 immunotherapy, eftilagimod alfa, in combination with KEYTRUDA and chemotherapy for metastatic non-small cell lung cancer, aiming for patient enrollment by early 2025.
Significance of Trial: This trial represents a crucial advancement for Immutep in the biotech industry, potentially establishing a new standard of care for this type of cancer following approvals from Australia and expected global clearances.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
